
Riluzole and Sorafenib in Patients With Advanced Solid Tumors: A Phase I Trial
April 12, 2023
Our phase I study determined the tolerable dose of this combination and investigated its biologic effects.” BUFFALO, NY- April 12, 2023 – A new research paper was published in Oncotarget's... read more